Last Update 07 Mar 26

Fair value Decreased 1.65%

KURA: Komzifti Launch Execution And AML Trial Data Will Drive Upside

The average analyst price target for Kura Oncology has shifted slightly as updates around Komzifti's launch, expected market share, and recent Q4 results have led analysts to fine tune their models, with some lifting targets to levels such as $30 and others trimming them to levels like $20 and $36.

Analyst Commentary

Recent Street research on Kura Oncology reflects a mix of optimism around Komzifti's launch and caution around execution and competitive dynamics. Price targets have been adjusted both higher and lower as analysts update models for early sales, preliminary Q4 figures, and management's guidance.

Bullish Takeaways

Bullish analysts see Komzifti's early launch feedback as encouraging, pointing to safety, convenience, and potential for use in combinations as key support for their long term growth assumptions.
Some analysts argue that recent Q4 updates have strengthened their view of the overall story, which supports higher valuation ranges such as the move to a US$30 price target.
There is continued confidence from some on Komzifti's positioning in the r/r NPM1m setting, with expectations that the product can secure a strong share even in a shared market.
Model revisions that incorporate Komzifti net product revenue, collaboration revenue, and management's 2026 guidance are still supporting Outperform ratings, which suggests analysts see room for execution to translate into value over time.

Bearish Takeaways

Bearish analysts, or those trimming targets, point to investor expectations that were higher than the initial Komzifti launch feedback, which has led to reductions in some price targets to levels like US$20 and US$36.
The view that the treatment area is likely to be shared and not winner take all can cap how aggressively some analysts are willing to model long term revenue, which weighs on valuation estimates.
Updates to models ahead of Q4 that factor in preliminary Komzifti and collaboration revenue, as well as 2026 guidance, have resulted in lower target levels for some, reflecting a more cautious stance on execution and timing.
Even where ratings remain positive, the presence of recent target cuts signals that not all analysts are fully aligned on the pace of growth or how quickly current sales, such as the reported US$2.1m for Komzifti in the quarter following approval, translate into broader upside.

What's in the News

On January 28, 2026, Kura Oncology's board adopted amended and restated bylaws that reference the company’s certificate of incorporation for its registered office and agent, and update who can postpone, reschedule or cancel stockholder meetings (Changes in Company Bylaws/Rules).
The revised bylaws tighten and clarify rules around director nominations, including requiring nominating stockholders to be of record at the time of the meeting, limiting nominees to the number of open seats, prohibiting substitute nominees without timely notice, and setting explicit procedures for validating nominations (Changes in Company Bylaws/Rules).
Additional bylaw changes expand disclosure requirements for stockholder proposals and nominees, extend the window rules for submitting proposals when annual meeting dates move, and incorporate universal proxy rules under the Securities Exchange Act of 1934 (Changes in Company Bylaws/Rules).
Kura Oncology and Kyowa Kirin reported new data for KOMZIFTI (ziftomenib) in combination with venetoclax and azacitidine in the KOMET-007 Phase 1a/1b trial in acute myeloid leukemia, with the combination described as having a favorable safety profile and encouraging antileukemic activity in both newly diagnosed chemotherapy ineligible and relapsed or refractory settings (Product Related Announcements).
The KOMZIFTI combination data are being presented in two oral sessions at the 67th American Society of Hematology Annual Meeting, alongside commentary on ongoing registrational trials, collaboration risks, regulatory uncertainties and the possibility that future results or approvals may differ from current expectations (Product Related Announcements).

Valuation Changes

Fair value was trimmed slightly from $33.00 to $32.45.
The discount rate was nudged higher from 7.05% to 7.12%.
Revenue growth was revised up from 53.03% to 92.49%.
The net profit margin was adjusted down from 16.24% to 10.89%.
The future P/E was kept broadly stable, moving from 70.89x to 70.76x.

12 views

Key Takeaways

Anticipated drug approvals and a diverse pipeline in high-need oncology segments set the stage for accelerated revenue growth and market expansion.
Strategic partnerships and industry trends support strong financial positioning, reduced risk, and sustainable long-term earnings potential.
Reliance on successful drug development amid mounting losses, regulatory uncertainty, strong competition, and funding constraints threatens future market access, profitability, and shareholder value.

Catalysts

About Kura Oncology

A clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.What are the underlying business or industry changes driving this perspective?

The expected FDA approval and commercial launch of ziftomenib for relapsed/refractory NPM1-mutant AML, along with positive priority review signals and strong KOL feedback, could drive rapid revenue growth and early market share capture in a high unmet need segment.
The ongoing initiation of two Phase III frontline AML trials (KOMET-017), leveraging accelerated approval pathways and trial efficiencies, positions Kura to potentially expand its addressable market to over $7 billion annually-substantially improving long-term revenue and earnings prospects if successful.
Kura's expanding pipeline, including next-generation farnesyl transferase inhibitors and menin inhibitors for broader indications (GIST, diabetes, solid tumors), provides multiple shots on goal that diversify risk and could result in future revenue streams and margin expansion.
The company's strategic partnership with Kyowa Kirin enables non-dilutive funding through milestone payments (up to $375M near-term milestones), supports commercial scale-up, and eases financing risks, collectively improving cash burn rates and potential net margins.
Secular factors such as the rising global cancer incidence, the shift toward precision, targeted therapies (areas Kura is focused on), and faster, biomarker-driven drug approval processes, are expanding demand for innovative oncology solutions, anchoring sustainable long-term revenue growth as Kura's therapies come to market.

Kura Oncology Earnings and Revenue Growth

Kura Oncology Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Kura Oncology's revenue will grow by 73.5% annually over the next 3 years.
Analysts are not forecasting that Kura Oncology will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Kura Oncology's profit margin will increase from -236.8% to the average US Biotechs industry of 16.1% in 3 years.
If Kura Oncology's profit margin were to converge on the industry average, you could expect earnings to reach $69.8 million (and earnings per share of $0.66) by about September 2028, up from $-197.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $259.1 million in earnings, and the most bearish expecting $-459.4 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 49.9x on those 2028 earnings, up from -3.7x today. This future PE is greater than the current PE for the US Biotechs industry at 15.5x.
Analysts expect the number of shares outstanding to grow by 7.0% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.78%, as per the Simply Wall St company report.

Kura Oncology Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Kura Oncology remains pre-revenue with increasing net losses ($66.1M in Q2 2025 vs. $50.8M in Q2 2024) and a rapidly declining cash position ($630.7M as of June 2025 vs. $727.4M at end-2024), meaning delays in product approvals or commercialization could necessitate dilutive fundraising, directly impacting earnings per share and shareholder value.
The company faces significant clinical development risk, as lead candidate ziftomenib awaits its first FDA approval (with a PDUFA date of Nov 2025) and is still enrolling pivotal Phase III trials for frontline AML-any clinical failure or regulatory delay would materially impact anticipated revenue growth and prolong unprofitable operations.
Heightened competition, particularly from larger, better-resourced players like Janssen (J&J) with a menin inhibitor already in Phase III for similar AML populations, could erode Kura's potential future market share and pricing power, materially limiting long-term revenue and net margin expansion.
Payer resistance to covering expensive novel therapies-especially as healthcare cost containment and regulatory scrutiny on drug pricing intensifies-could restrict market access and result in downward pressure on expected revenues and gross margins for Kura's prospective products.
Ongoing reliance on milestone payments from collaborations (e.g., Kyowa Kirin agreement) introduces uncertainty to financial planning, and any underperformance in achieving these milestones, along with tightening capital markets, could constrain available funding for clinical development, increasing financial risk and impeding future earnings growth.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $27.0 for Kura Oncology based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $11.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $434.8 million, earnings will come to $69.8 million, and it would be trading on a PE ratio of 49.9x, assuming you use a discount rate of 6.8%.
Given the current share price of $8.43, the analyst price target of $27.0 is 68.8% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Kura Oncology?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Upcoming FDA Approval Will Open New Oncology Avenues